A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. by Mannelli, F et al.
Cytometry Part B (Clinical Cytometry) 84B:71–81 (2013)
A Systematic Analysis of Bone Marrow Cells by
Flow Cytometry Defines a Specific Phenotypic
Profile Beyond GPI Deficiency in Paroxysmal
Nocturnal Hemoglobinuria
Francesco Mannelli,1,2* Sara Bencini,1,2 Benedetta Peruzzi,3 Ilaria Cutini,1,2
Alessandro Sanna,1,2 Matteo Benelli,4 Alberto Magi,5 Giacomo Gianfaldoni,1,2
Giada Rotunno,1,2 Valentina Carrai,1,2 Anna Maria Grazia Gelli,3 Veronica Valle,6
Valeria Santini,1,2 Rosario Notaro,2 Lucio Luzzatto,2 and Alberto Bosi1,2
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Background. Paroxysmal nocturnal hemoglobinuria (PNH) is a unique disorder caused by a PIG-A gene
mutation in a stem cell clone. Its clinical picture can sometimes make challenging the distinction from other
disorders, and especially from myelodysplastic syndromes (MDS), since both diseases correlate with cytope-
nias and morphological abnormalities of bone marrow (BM) cells. Recently, flow cytometry (FC) has been pro-
posed to integrate the morphologic assessment of BM dysplasia, and thus to improve the diagnostics of MDS.
Methods. In the present study, we have analyzed systematically FC data resulting from the study of
BM cells from patients with PNH and MDS.
Results. Our data demonstrated abnormalities in PNH beyond the deficiency of glycosylphosphatidyli-
nositol-linked proteins and the application of a systematic approach allowed us to separate effectively
MDS and PNH in a cluster analysis and to highlight disease-specific abnormalities. Indeed, the parallel
evaluation of some key parameters, i.e. patterns of expression of CD45 and CD10, provided information
with practical diagnostic usefulness in the distinction between PNH and MDS. Moreover, the hypo-
expression of CD36 that we observed on monocytes might be related to the thrombotic tendency in PNH.
Conclusions. We investigated systematically the phenotypic profile of BM cells from patients with PNH; our
data provide useful antigenic patterns to solve between PNH and MDS, sometimes morphologically overlap-
ping. Moreover, some PNH-related phenotypic changes might be involved in the physiopathology of the disease
and further studies addressing this issue are warranted.VC 2012 International Clinical Cytometry Society
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Paroxysmal nocturnal hemoglobinuria (PNH) is a
unique disorder caused by a PIG-A gene mutation in a
stem cell clone [1,2]. As a consequence, blood cells com-
pletely or partially lack surface proteins that are tethered
to the membrane through the glycosylphosphatidylinositol
(GPI) anchor [3,4]. The resulting absence of CD55 and
CD59 molecules on red cells renders them sensitive to
complement-mediated intravascular hemolysis and associ-
ated hemoglobinuria [5]. PNH often shows a component
of bone marrow (BM) failure, which sometimes deter-
mines pancytopenia. This clinical picture can make it chal-
lenging to distinguish PNH from other cytopenia-causing
disorders, and especially from myelodysplastic syndromes
(MDS). There are pathophysiological links between MDS
and PNH and PNH clones can be detected in a relevant
fraction of MDS patients. The presence of such small pop-
ulations of GPI-deficient cells correlates with important
prognostic and therapeutic implications in the setting of
MDS. The International PNH Group has, therefore, defined
these conditions as subclinical PNH [6].
The diagnosis of PNH and its distinction from MDS
strictly rely on a specific clinical suspicion, which drives
the application of diagnostic techniques and interpretation
of the results. Indeed, morphology still represents the cor-
nerstone for the diagnosis of MDS: dysplastic features in a
significant fraction of BM cells provide evidence of ineffec-
tive hemopoiesis, which is the common denominator of
this heterogeneous group of disorders [7]. However, mor-
phological abnormalities overlapping with those observed
in MDS have been described in PNH and are considered
part of the spectrum of its hematological picture [8]. It is
important to note that not even an abnormal karyotype
can rule out a diagnosis of PNH, since abnormalities have
been reported in up to 24% of patients [8].
Flow cytometry (FC) is established as the method of
choice for diagnosing PNH [9,10]; nevertheless, a specific
analysis aiming at this depends on the clinical suspicion.
In fact, it includes the study of GPI-related molecules on
red cells and it is performed on peripheral blood (PB),
whose analysis is less prone to be misinterpreted than on
BM, due to the dependency on maturation of some GPI-
related antigens. Many reports have proposed FC as a
useful technique in the diagnosis of MDS, mainly by
investigating the expression of key antigens during matu-
ration [11–15]. Such an approach on BM samples in view
of cytopenia may not be able to distinguish PNH from
MDS. On the other hand, the progressive role of FC as a
reliable technique to investigate dysplasia gives the op-
portunity to get an insight into PNH phenotype, beyond
GPI-dependent abnormalities. In the present study, we
have carried out a systematic analysis of BM samples
from patients with PNH and MDS; our aim was to com-
pare the whole BM phenotypic profile in order to pin-
point distinctive patterns associated with these diseases.
MATERIALS AND METHODS
Patients, Controls, and Samples
Patients with untreated PNH (n¼8) and MDS (n¼30)
were included in the study. BM samples were sent to
our laboratory in view of cytopenia to address the suspi-
cion of MDS. On the basis of a parallel analysis on PB
(see below), when clinically required, some patients
were eventually demonstrated to have PNH. MDS cases
were classified according to WHO [7]. BM samples from
21 healthy donors and patients with lymphoma at stag-
ing without BM involvement were included as controls.
Some patients with vitamin B12 deficiency (B12 def)
were studied by the same approach as a ‘‘positive’’ con-
trol (morphologic dysplasia due to a different cause). All
samples were fresh and anti-coagulated with EDTA. The
study was approved by an institutional review board,
and the patients were enrolled after obtaining a written
informed consent from them in accordance with the
Declaration of Helsinki.
Morphologic Analysis
For MDS diagnosis, according to WHO [7], at least
10% of the cells of at least one myeloid BM lineage (ery-
throid, granulocytic, megakaryocytic) had to show
unequivocal dysplasia on May–Grunwald–Giemsa-stained
BM aspirates.
Karyotyping and IPSS Assessment
Cytogenetic analysis was performed on BM cells at di-
agnosis according to the International System for Human
Cytogenetic Nomenclature [16]. International prognostic
scoring system was assessed according to published evi-
dences [17].
BM FC Analysis
Cells, 2 x 106 of a fresh BM suspension, were stained
for surface markers using a stain-lyse-and-then-wash pro-
cedure; intracellular nuclear and cytoplasmic staining
were performed after cell fixation and permeabilization,
using the Fix and Perm reagent kit (Invitrogen, Carlsbad,
CA, USA). The following combinations of monoclonal










Clones of MoAbs were as follows: HLA-DR: G46-6;
CD117: YB5.B8; CD45: HI30; CD34: 581; CD123: 7G3;
CD11b: M1/70; CD13: WM15; CD22: S-HCL-1; CD33:
HIM3-4; CD15: HI98; CD16: 3G8; CD71: M-A712; CD105:
SN6; CD2: RPA-2.10; CD56: MY31; CD65: 88H7; NG2:
7.1; CD36: CB38; CD64: 10.1; CD14: M5E2; CD203c:
97A6; CD38: HB7; nTdT: HT-6; cyMPO: MPO-7; CD19:
4G7; cyCD79a: HM-57; cyCD3: HIT3a; CD7: M-T701.
All MoAbs were purchased from Becton Dickinson
(BD,San Jose, CA, USA), excluding nTdT, cyMPO (Dako,
Glostrup, Denmark), CD11b, CD65, CD203c (Immuno-
tech, Marseille, France), and CD105 (e-Bioscience, San
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Diego, CA, USA). Data acquisition was performed using
a FACSCalibur flow cytometer (BD) and Cell Quest Pro
software (BD). A total of 50,000 events of BM cellularity
per tube was acquired; if required, a second step was
performed in order to collect at least 1 x 103 CD34þ
cells through an electronic gate. For data analysis,
FIG. 1. Multiple abnormalities detected by flow cytometry in the bone marrow cells of MDS and PNH patients: illustrated examples. Bivariate dot
plots illustrating how the different cell compartments were identified on the basis of light scatter characteristics and reactivity for CD45 PerCP and
CD34 APC (A,B,D,E,G,H). Identification of the different subsets within neutrophil compartment on the basis of the combined expression of CD13 and
CD11b (C,F,I). Dot plots were created by using Infinicyt software. [Color figure can be viewed in the online issue which is available at
wileyonlinelibrary.com]
DISTINCTIVE PHENOTYPE OF PNH BONE MARROW CELLS 73
Cytometry Part B: Clinical Cytometry
Infinicyt (Cytognos SL, Salamanca, Spain) software was
used. Our approach was adapted from the one
described by Matarraz et al. [13]. Briefly, some major BM
cell compartments were identified on the basis of for-
ward (FSC) and sideward (SSC) light scatter characteris-
tics and their reactivity for CD45 and CD34 (Figs
1A,B,D,E,G,H). These subsets were (i) myeloid CD34þ/
nTdT-/CD117þ fraction of CD34þ cells; (ii) CD34þ B-
cell precursors, featured by HLA-DRhi/CyMPO-/nTdTþ/
CD117- profile with low SSC; (iii) maturing granulocytic
compartment, selected on the basis of CD45þdim/
CD34- with high SSC, within which four maturation
stages were identified depending on reactivity for CD13
and CD11b (Fig. 1 C,F,I); (iv) mature monocytic com-
partment (CD45þhi/CD34- with intermediate SSC sig-
nal); and (v) mature erythroid compartment (CD45-/
CD34- with low SSC). A series of 69 phenotypic parame-
ters were defined (17 for CD34þ, 27 for neutrophil, 15
for monocytic, and 10 for erythroid compartment) and
expressed as percentage of positive cells for a given anti-
gen within a cell compartment and/or its mean fluores-
cence intensity (MFI; arbitrary relative linear units,
scaled from 0 to 104). Normal phenotypic profile was
defined on normal BM samples as the interval between
mean value  two standard deviations for each parame-
ter. Phenotypic aberrancies in MDS, B12 def, and PNH
were defined considering deviations from the normal
profile. Daily instrument quality controls including fluo-
rescence standardization, linearity assessment, and spec-
tral compensation were performed to ensure identical
operation from day to day according to published evi-
dence [18,19]. Specifically, instrument setup, calibration,
and quality control were checked during the study using
commercial standard reagents (Spherocaliflow QC kit;
Spherotec, Lybertyville, IL, USA).
PNH FC Analysis on PB
PNH diagnosis was performed by FC on PB as else-
where described [9,20]. Data acquisition was carried out
by a FACS Canto II (BD) flow cytometer; for data analy-
sis, Diva Software (BD) was used. Analysis of red blood
cells (RBC) was performed on 3 ll of PB diluted 1:200
with PBS; 50 ll of the diluted sample were incubated
with anti-CD59 PE MoAb (Clone MEM43, Serotec) for
15 min in the dark at room temperature and washed
twice with PBS. A total of 20,000 events of PB cellularity
per tube was acquired. Analysis of white blood cells
(WBC) was performed on 60 ll of PB incubated with a
combination of CD66b FITC, CD33 PE, CD45 PerCP-Cy-
5.5, and CD14 APC MoAbs (all purchased from BD) for
15 min in the dark at room temperature. After incuba-
tion, the samples were incubated with an erythrocyte-
lysing reagent (2 ml), then washed twice with PBS. A
total of 20,000 events of CD45-positive cells per tube
was acquired. Neutrophils and monocytes were identi-
fied on the basis of CD45 vs SSC dot plot as a first step,
and further purified through CD33 expression intensity
as a second step. GPI-deficient cells were defined by
negativity for CD66b on neutrophils, CD14 on mono-
cytes, and CD59 on RBC.
Statistical Analysis
Data were processed using GraphPad InStat (Graph-
Pad Software, San Diego, CA USA) and SPSS (Statsoft Inc,
Tulsa, OK, USA) software. Comparisons between two or
more groups were performed using Mann–Whitney U
test. P values <0.05 were considered to be associated
with statistical significance. To test the capability of the
parameters in segregating different diseases, we per-
formed Ward’s hierarchical clustering. Briefly, data were
stored in a database system (Microsoft Excel; Microsoft,
Seattle, WA, USA) and were normalized. In order to nor-
malize the data of each individual, we calculated the
mean value of each parameter across all normal BM sam-
ples. Normalized data were obtained by dividing the
value of each individual by the calculated mean. Finally,
all the data were log2-transformed and the resulting nor-
malized log2 ratios were used for hierarchical clustering
analyses (custom R scripts, http://cran.r-project.org).
RESULTS
Patients’ Characteristics
From 2008 to 2011, BM samples from eight PNH
patients were studied; their characteristics are summar-
ized in Table 1. Five patients with B12 def were ana-
lyzed: B12 def was caused by nutritional deficiencies
(two cases), absorption alteration due to gastrectomy
(one case), and pernicious anemia (two cases). A total
Table 1


















1 35/M 3.92 10.9 87 129 980 11.3% 80.5% 79.7%
2 73/M 4.0 12.5 104 136 936 36.3% 56.0% 54.4%
3 59/F 4.7 9.3 109 122 1211 37.4% 70.6% 80.3%
4 80/M 7.4 9.9 109 292 447 18.5% 60.4% 63.4%
5 61/F 4.1 8.3 111 21 784 37.0% 76.0% 87.0%
6 62/M 2.9 8.7 104 105 1479 12.0% 91.0% 95.0%
7 28/M 2.4 6.9 96 46 327 17.0% 94.0% 89.0%
8 21/M 2.8 7.3 103 128 1447 15.6% 89.5% 90.4%
Abbreviations: PNH, paroxysmal nocturnal hemoglobinuria; LDH, lactate dehydrogenase; MCV, mean corpuscular volume; PMN,
poly-morpho-nuclear; RBC, red blood cells.
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Table 2
Phenotypic Characteristics of BM Cell Compartments
Phenotypic parameter Controls (#21) MDS (#30) B12 def (#5) PNH (#8) p1 p2 p3
CD34þ compartment
Total CD34þ % 1.0  0.4 4.1  4.1 1.3  0.6 0.1  0.1 0.003 ns 0.0006
B precursors 0.2  0.2 0.04  0.06 0.2  0.2 0.02  0.02 <0.0001 ns 0.0003
FSC MI 421  42 426  115 469  65 468  35 ns ns ns
SSC MI 59  6 62  15 65  12 67  3 ns ns 0.005
CD45 MFI 450  75 366  174 415  35 409  102 0.0006 ns ns
CD34 MFI 277  98 340  178 253  73 230  110 ns 0.003 ns
CD13 MFI 603  169 616  347 452  206 650  208 ns ns ns
CD33 MFI 380  136 358  253 222  60 460  188 ns ns ns
CD117 MFI 613  127 828  457 600  413 436  101 ns ns 0.003
HLA-DR MFI 1591  356 1596  1083 1325  685 1438  465 ns ns ns
CD7 % 14  2.7 21  17 16  3 27  11 ns ns 0.0001
MPO % 34  5 23  11 30  9 35  5 0.0003 ns ns
CD15 % 22  4 22  13 21  7 27  8 ns ns 0.01
CD65 % 22  6 15  7 17  5 16  4 0.0002 0.02 ns
CD11b % 1.6  1.6 5  8 2.8  1.3 1.5  1.8 ns ns ns
CD38 % 90  4 82  17 86  5 95  5 ns ns 0.02
CD25% 3  1.6 8  10 2  2.2 2  1.5 ns ns ns
Neutrophil compartment
Total neutrophil % 64  7 47  18 47  18 52  13 0.0002 0.004 0.008
FSC MI 662  40 637  120 745  109 632  75 ns ns ns
SSC MI 226  23 212  37 291  45 235  30 ns .002 ns
CD45 MFI 734  151 611  209 661  69 681  183 0.01 ns ns
CD15 MFI 6426  1090 6475  1965 6976  2691 6377  1507 ns ns ns
CD15 CV 26.1  11.5 32.5  16.5 29.9  18.5 30.0  10.0 ns ns ns
CD16 % 52  11 46  19 36  15 18  11 ns 0.03 0.0001
CD13 MFI 910  200 789  466 393  160 696  245 ns 0.0001 ns
CD11b MFI 959  155 1022  504 1221  962 914  186 ns ns ns
CD65 MFI 1542  481 1816  792 1848  735 1308  420 ns ns ns
CD33 MFI 251  111 363  288 283  74 136  68 ns ns ns
CD64 MFI 266  94 252  214 324  150 214  145 ns ns ns
CD10 % 49  13 42  16 30  10 60  19 ns 0.009 ns
CD123 % 4.8  7 8  8 20  17 3.1  4.0 ns 0.04 ns
CD4 % 16  6 29  24 24  5 11.5  6.6 0.03 ns ns
Stage I % 0.7  0.5 2.4  2.7 2.3  1.5 1.0  0.8 0.0004 0.002 ns
Stage II % 9.8  4.7 17.8  16.7 18.4  5.7 6.7  5.5 0.04 0.003 ns
Stage III % 36.6  7.3 29.8  13.6 44.4  5.5 30.0  13.2 0.03 0.03 ns
Stage IV % 53  10.7 50.1  18.8 34.9  12.5 62.5  18.4 ns 0.003 ns
Stage I FSC MI 681  78 621  125 705  128 636  65 ns ns ns
Stage II FSC MI 854  69 728  150 808  82 742  40 0.002 ns 0.002
Stage III FSC MI 716  63 655  132 756  138 644  65 ns ns 0.008
Stage IV FSC MI 648  57 608  117 777  141 580  65 ns ns 0.02
Stage I-III SSC MI 187  23 193  26 273  49 201  26 ns 0.0009 ns
Stage IV SSC MI 250  31 228  41 395  34 250  26 ns <0.0001 ns
Stage I-III CD45 353  111 441  138 396  63 321  80 0.03 ns ns
Stage IV CD45 MFI 702  289 758  259 638  100 680  264 ns ns ns
Monocytic compartment
Total monocytic % 4.4  0.95 5.8  5.8 5.0  3.7 4.0  2.2 ns ns ns
FSC MI 462  26 508  79 560  68 453  45 0.02 0.0009 ns
SSC MI 98  9 103  15 101  9 99  13 ns ns ns
CD45 MFI 1810  318 1638  567 1650  180 1619  287 ns 0.002 ns
CD14 % 90  4 81  15 90  6 25  14 ns ns <0.0001
CD14 MFI 1367  321 907  550 1155  292 384  220 0.006 ns <0.0001
CD45 MFI CD14neg 951  110 918  166 877  80 1629  143 ns ns <0.0001
CD45 MFI CD14pos 2088  308 1743  423 1896  86 1752  119 0.02 ns ns
CD36 MFI 1245  320 925  514 1439  1240 356  156 0.003 ns <0.0001
CD64 MFI 1681  369 1885  788 1585  326 1392  750 ns ns ns
CD13 MFI 1756  718 1440  997 1570  1110 1540  356 ns ns ns
CD11b MFI 1395  290 1249  714 1604  1109 1308  532 0.02 ns ns
CD15 MFI 545  186 1160  1014 600  330 817  406 0.01 ns ns
CD33 MFI 1085  515 1445  796 1000  205 997  437 ns ns ns
CD65 MFI 212  143 351  259 224  61 152  75 ns ns ns
Erythroid compartment
Total erythroid % 9.9  5.6 20.6  13.3 30.3  13.3 18.9  14.4 0.002 <0.0001 ns
FSC MI 226  14 258  45 283  28 238  30 0.01 <0.0001 ns
SSC MI 20  2.7 28  9 30  12 24  5 <0.0001 0.002 0.03
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of 30 patients with newly diagnosed MDS were investi-
gated; according to WHO, they were classified as fol-
lows: RA (eight patients); RARS (refractory anemia with
ring sideroblasts) (one); RCMD (refractory cytopenia
with multilineage dysplasia) (seven); myelodysplastic
syndrome-unclassified (one); RAEB-1 (refractory anemia
with excess blasts) (nine); and RAEB-2 (four). According
to IPSS, they were stratified as follows: low risk, 10
cases; intermediate-1, 9; intermediate-2, 8; high risk, 3.
Phenotypic Analysis of MDS Compared to Controls
The phenotypic parameters of MDS were individually
compared to analogue control values (Table 2). As al-
ready described by several reports [11–14], one finding
emerging from our study concerned precursor B cells,
not detectable in the majority (70%) of MDS patients.
Furthermore, several alterations emerged in MDS within
CD34þ and mature compartments.
Phenotypic Analysis of B12 def Compared to Controls
Some abnormalities within the granulocytic compart-
ment were specifically associated with B12 def: SSC sig-
nal was increased compared to controls, as it likely
expressed the phenotypic counterpart of hyperseg-
mented cells, often observed morphologically. Erythroid
compartment showed several alterations, primarily
regarding its relative percentage on global cellularity,
which was significantly increased. Furthermore, ery-
throid cells had higher FSC and SSC, and a trend to a
weaker expression of CD36 and CD71 compared to
controls.
Phenotypic Analysis of PNH Compared to Controls
The analysis of BM from PNH patients showed some
significant deviations. Some of them were linked to lack
of GPI, whereas others were not. With respect to
CD34þ cells, either their total amount or B lymphoid
precursors were reduced; B precursors were undetect-
able in five out of eight cases. Higher percentages of
positivity for CD7 and CD38 were observed on PNH
CD34þ cells compared to the normal reference. Within
granulocytic compartment, the percentage of CD16-
highly positive neutrophils was lower than in controls;
this finding is consistent with the GPI-dependent tether-
ing of CD16. No further relevant changes emerged for
granulocytic compartment. With regard to monocytic
cells, CD14 pattern was obviously influenced by the
lack of GPI and resulted significantly lower than in
Table 2
Phenotypic Characteristics of BM Cell Compartments (Continued)
Phenotypic parameter Controls (#21) MDS (#30) B12 def (#5) PNH (#8) p1 p2 p3
CD45 MFI 7  4 12  11 19  12 8.6  4.3 0.01 0.004 ns
CD36 % 96  6 78  24 72  20 92  6 <0.0001 0.0009 ns
CD36 MFI 1704  234 1170  650 1125  452 834  294 <0.0001 0.01 <0.0001
CD105 % 21  6 23  16 37  30 19  8 ns ns ns
CD105 MFI 190  76 208  178 451  670 130  25 ns ns 0.01
CD71 MFI 3207  1050 2000  1478 1077  1214 1228  1019 0.004 0.006 0.006
CD71 CV 42  9 108  97 140  6 73  13 <0.0001 <0.0001 <0.0001
Abbreviations: MDS, myelodysplastic syndromes; B12 def, vitamin B12 deficiency; PNH, paroxysmal nocturnal hemoglobinuria;
FSC, forward light scatter; SSC, sideward light scatter; MFI, mean fluorescence intensity (arbitrary units); %, percentage of positive
cells within relative compartment; CV, coefficient of variation; ns, not significant. Data are expressed as mean  one standard devi-
ation. p1: controls vs MDS; p2: controls vs B12; p3: controls vs PNH.
FIG. 2. Multi-parameter analysis of bone marrow samples demonstrates disease-related quantitative abnormalities, appraised by a validated pheno-
typic score [21]. Box plots were generated by SPSS software. Boxes represent the interquartile range that contains 50% of the subjects, the horizon-
tal line in the box marks the median, the small square inside indicates mean value and bars show the range of values. NBM, normal bone marrow;
B12, vitamin B12 deficiency; PNH, paroxysmal nocturnal hemoglobinuria; MDS, myelodysplastic syndromes. [Color figure can be viewed in the
online issue which is available at wileyonlinelibrary.com]
76 MANNELLI ET AL.
Cytometry Part B: Clinical Cytometry
FIG. 3. Cluster analysis of normal bone marrows, PNH, MDS, and vitamin B12 deficiency: PNH cases grouped in a separate cluster due to a dis-
tinctive phenotypic profile. Cluster analysis of normal bone marrow (NBM), MDS (each case with relative IPSS score), PNH, and B12 deficiency
(B12 def) based on the phenotypic parameters within distinct subsets of BM cell compartments. GPI-related antigens were excluded from this analy-
sis. Rows represent individual BM samples from NBM, MDS, PNH, and B12 def; columns represent the normalized log2 ratios of the percentage of
individual cell subsets and the mean fluorescence intensity (MFI; arbitrary relative linear units) obtained for each marker analyzed in a given cell
population divided by the mean value obtained for that parameter in all control samples. The value of each parameter is represented in a color code
according to control values: red represents expression greater than the mean, green represents expression lower than the mean; color intensity repre-
sents the magnitude of the deviation from the mean. [Color figure can be viewed in the online issue which is available at wileyonlinelibrary.com]
FIG. 4. Distinctive pattern for CD14 and CD45 on monocytes in PNH cases. Histogram plots show the pattern of CD45 on monocytes, gated by
CD33 intensity, according to CD14 expression in three illustrative bone marrow samples from controls (panel A), MDS (B), and PNH (C) groups.
CD14-negative monocytes in PNH showed significantly higher levels of CD45 relative to their counterparts in normal BM or MDS, which is consistent
with the GPI-related lack of CD14 that is independent on maturation stage. Histogram and dot plots were created by using Infinicyt software. [Color
figure can be viewed in the online issue which is available at wileyonlinelibrary.com]
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controls. One unexpected finding concerned a GPI-unre-
lated molecule: CD36 intensity was reduced relative to
normal. In five cases, it was possible to address the
expression of CD36 according to CD14: CD14-negative
and CD14-positive monocytes expressed similar amounts
of CD36 (mean MFI 554.44 vs 556.26, ns). Erythroid
compartment showed increased SSC, a weaker and more
heterogeneous expression of CD71 and an abnormal pat-
tern for CD36. Of note, CD36 was maintained in terms
of percentage of positivity, while its expression was
globally less intense than on normal counterpart.
Phenotypic Scores in MDS, B12 def, and PNH
In order to estimate the degree of abnormality, we
applied a previously described and validated phenotypic
score [21] to our cases. The mean scores assigned to
PNH and B12 def were generally lower than for MDS
(Fig. 2A) but PNH cases had a remarkable overlap with
MDS. Since phenotypic score included some GPI-linked
antigens, we repeated our analysis after excluding the
relative parameters (i.e. CD14 percentage on monocytes,
CD16 percentage on neutrophil compartment). As we
can infer from the resulting plot (Fig. 2B), PNH score
continued to be abnormal and overlapping with MDS
even when counting out GPI deficiency.
Cluster Analysis: Identification of a Distinctive
Phenotypic Profile for PNH
We performed a two-step cluster analysis to verify the
capability of the whole phenotypic profile to separate
different diseases: i) an unsupervised analysis including
all 69 parameters; ii) an analysis excluding GPI-related
antigens, to get further insights into abnormalities not
dependent on GPI. PNH patients clustered in both analy-
sis (i) (see Supplemental data) and (ii) (Fig. 3). We then
revised the results of the clustering analysis, aiming to
pinpoint disease-specific patterns. Abnormalities in
erythroid compartment were shared by all disease
categories. No single erythroid phenotypic abnormality
was specifically associated with any disease group;
rather, direction and extent of abnormalities appeared
independent of the underlying condition. CD36 expres-
sion pattern was assessed by both percentage and inten-
sity. The combination of the two parameters was
different in PNH, since CD36 was maintained in terms
of percentage but less intense. In MDS and B12 def, the
percentage and the intensity were both abnormally
reduced. Given the potential variability in CD36 MFI,
due to the presence of a bi-modal expression, we esti-
mated its value focusing on CD36-positive population:
this approach confirmed this antigen to be hypo-
expressed in PNH (mean MFI 790.64) compared to nor-
mal BM (1781.70; p<0.0001). The mere analysis of GPI-
linked antigens would have not been sufficient to distin-
guish PNH from MDS. Indeed the pattern of these anti-
gens in some MDS cases mimic what was observed in
PNH. As an example, in our series, 11 of 30 (36.7%)
MDS cases displayed a CD14-negative monocytic popula-
tion equal to or higher than 20% of cells within relative
compartment, likely as a consequence of impaired matu-
ration. The parallel trend of CD45 aided to differentiate
between MDS and PNH: CD14-negative monocytes in
FIG. 5. Distinctive pattern for CD10 and CD16 on granulocytic compartment in PNH cases. Dot plots display the pattern of CD16 and CD10 within
the bone marrow granulocytic compartment (blue color; gated on the basis of CD45 reactivity and SSC) in two illustrative cases of PNH (panels A–B)
and MDS (C–D). MDS show a parallel decrease of CD16hi and CD10þ elements whereas CD10 expression is preserved in PNH. Histogram and dot
plots were created by using Infinicyt software. [Color figure can be viewed in the online issue which is available at wileyonlinelibrary.com]
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PNH showed significantly higher levels of CD45 relative
to their counterpart in MDS (and even in normal BM)
(Fig. 4). Similarly, CD16-highly positive granulocytic cells
were frequently reduced in MDS (48% of cases) com-
pared to controls; in these cases, we observed a parallel
decrease of CD10 expression that was maintained in
PNH instead (Fig. 5). Clustering of PNH cases was essen-
tially provided by the simultaneous assessment of the
whole phenotypic profile, rather than by single abnor-
malities. The very fact that PNH cases clustered to-
gether, even after removing GPI-related parameters,
confirmed further that PNH shows a distinctive pheno-
typic profile exceeding GPI-dependent antigens.
DISCUSSION
MDS and PNH have remarkable overlapping areas,
ranging from pathogenesis to clinical picture. PNH
clones can be detected in the setting of MDS, and their
presence may not be related to the pre-leukemic nature
of MDS but rather linked to BM failure, similar to aplas-
tic anemia [22]. Furthermore, PNH can represent the
clinical evolution of another BM disorder, and especially
of MDS cases.
Due to clinical and morphological similarities, the dis-
tinction between MDS and PNH can sometimes be diffi-
cult. We have analyzed systematically flow cytometry
(FC) data resulting from the study of BM cells from
patients with MDS and PNH. In the latter disease, the
observed phenotypic changes were beyond the
expected GPI-related abnormalities. The total amount of
CD34þ cells on global cellularity was reduced. This find-
ing has already been reported [23] and is not surprising
taking into consideration the autoimmune-mediated
attack that provides a relative advantage to PNH clone
[24]. The proportions among CD34þ subpopulations
were also affected: B lymphoid precursors were not de-
tectable in the majority of our cases and the mean per-
centage of CD34þ/CD38þ fraction was higher than in
normal BM. The latter finding is consistent with the
reduced frequency of the most immature CD34þ/
CD38 subpopulation, about which Elebute et al. have
previously reported, suggesting a stem cell defect in the
pathogenesis of PNH [25]. The antigenic profile of
CD34þ cells did not show relevant abnormalities; the
increased expression of CD7 was probably related to B
precursors reduction, since CD7 is normally expressed
by a fraction of myeloid CD34þ cells. These data paral-
lel the lack of significant differences in gene expression
profiles between CD34þ cells from PNH patients and
healthy individuals described by Chen et al. [26]. As for
morphology, several abnormalities on maturing cell com-
partments emerged. Our systematic approach combining
all parameters allowed us to overcome the overlap with
MDS that was described by morphology. Specifically, the
simultaneous assessment of some phenotypic marks was
distinctive for PNH. The trend of expression of CD45
and CD10, if analyzed in parallel with GPI-linked anti-
gens, allowed to work out phenotypic changes as being
associated with MDS rather than PNH. CD14 and CD16
are acquired within respective lineage at the final stages
of maturation. In normal BM, a relevant fraction of cells
are physiologically negative for these antigens, and in
MDS, these fractions quite often increase, most likely as
a result of impaired maturation. The parallel pattern of
CD14 and CD45 on monocytes aided in distinguishing
between MDS and PNH, since CD45 increases along
with monocytic maturation. CD14-negative monocytes
in PNH showed significantly higher levels of CD45 rela-
tive to their counterparts in MDS, which is coherent
with the GPI-related lack of CD14, mainly independent
on maturation stage (Fig. 4). Analogue mechanism
accounted for the dissociation between CD10 and CD16
in the granulocytic compartment in PNH compared to
MDS (Fig. 5).
The careful assessment of these parameter combina-
tions can be very useful in the diagnostic process of cyto-
penia, especially when FC analysis is not driven toward
PNH by a specific clinical query, and furthermore
because some MDS-related abnormalities concern GPI-
linked molecules. In this respect, it is important not to
miss PNH in a patient thought to have MDS, primarily
because of the high risk of thrombosis associated with
the former disease. Furthermore, some phenotypic
changes emerging from our data might be related to PNH
physiopathology. Monocytic and erythroid compartments
appeared to express lower levels of CD36 compared to
controls. It was interesting to observe that erythroid line-
age in MDS and B12 def shared similar patterns of CD36
abnormality (i.e. decreased percentage of CD36-positive
cells), reasonably attributed to ineffective erythropoiesis.
On the contrary, PNH showed CD36 hypo-expression
with normal percentage, probably due to a different
mechanism. As the hypo-expression of CD36 on mono-
cytic cells did not depend on belonging to PNH clone, it
could be related to external factors influencing the
expression on both normal residual and PNH cells. CD36
is a glycoprotein belonging to the scavenger receptor
type B family and is expressed in a variety of cells and tis-
sues [27]. CD36 and CD36-related pathways have been
involved in the pathogenesis of atherosclerosis and
thrombosis [27]. Some published evidence suggests that a
reduction in CD36 expression on monocytes might be re-
sponsible of a thrombophilic state. First, CD36 is involved
in the release of arachidonic acid from cell membranes
and thus contributes to the generation of proinflamma-
tory eicosanoids. Monocytic cells null for CD36 have
been reported to produce paradoxically more prostaglan-
din E2, probably as a result of compensatory up-regula-
tion of cyclooxygenase [28]. Furthermore, the release of
pro-coagulant phospholipid micro-particles from PNH
erythrocytes by complement activation has been pro-
posed as a mechanism of PNH-related thrombophilia
[29]. Given the role of CD36 in scavenging of cell-derived
micro-particles, one might surmise a reduction of this
process due to the molecule hypo-expression. As such,
our data deserve further investigation in order to get an
insight into the potential participation to the well-estab-
lished PNH-related thrombophilic state [30].
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In conclusion, this study allowed us to investigate sys-
tematically the phenotypic profile of BM cells from
patients with PNH; our data provided useful antigenic
patterns to distinguish between PNH and MDS. Besides,
some PNH-related phenotypic changes might be
involved in the physiopathology of the disease and fur-
ther studies addressing this issue are warranted.
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